22 June 2024-Quebec
Nexera Pharmaceuticals (TSX: NEX) has announced the successful completion of a listing agreement with the Government of Quebec for Trecondy® (treosulfan for injection). As a result, the Régie de l’Assurance Maladie du Québec (RAMQ) will now reimburse eligible claims for Trecondy® through the province’s Public Prescription Drug Insurance Plan.
“This is a significant reimbursement milestone for Trecondy®, as we have now secured public reimbursement in Canada’s three most populous provinces, covering approximately three-quarters of the national population,” said Santi Pagoda, Chief Operating Officer at Nexera Pharmaceuticals. “This achievement reflects our commitment to expanding access to innovative therapies across Canada and highlights the growing potential of our treosulfan portfolio—both Trecondy® in Canada and GRAFAPEX™ (treosulfan for injection) in the United States.”
“This achievement reflects our commitment to expanding access to innovative therapies across Canada...”
– Santi Pagoda
Nexera continues to work closely with additional provincial, territorial, and federal authorities to secure public reimbursement for Trecondy® in remaining jurisdictions. The company remains dedicated to making this important therapy available to all eligible patients across Canada as swiftly as possible.
About Trecondy®
Trecondy® (treosulfan for injection) is indicated for use as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).
